 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced the Company will present a poster at IMMUNOLOGYTM 2022, the annual meeting of the American Association of Immunologists AAI. The meeting will be held May 6-10, 2022, in Portland, Oregon. Presentation Details Proteomic analysis of plasma 